The 2025-2030 World Outlook for Empty Capsules

The 2025-2030 World Outlook for Empty Capsules

This study covers the world outlook for empty capsules across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of empty capsules as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include ACG, Advinus Therapeutics, AstraZeneca, Aventis, Baotou Capstech Company, Bend Research, Inc., Biogen Idec, Boehringer Ingelheim, Bright Pharma Caps, Caps Canada, Capsugel, Cardinal Health, Catalent, Celgene, Chelsea Therapeutics, Cipla, Comed Chemicals Limited., Dr. Reddy's Laboratories, Drug, Chemical & Associated Technologies Association (DCAT), Eli Lilly, European Federation of Pharmaceutical Industries and Associations (EFPIA), Food and Drug Administration (FDA), Fortcaps., Fruit d'Or Nutraceuticals, Gelita, Genix Industria Farmaceutica, Ltd.a., Genzyme, GlaxoSmithKline, Goerlich Pharma, HCARE LIMITED., Healthcaps India, Healthy Directions LLC., Helen of Troy, Helsinn Healthcare, HTC Group, Ltd., India Brand Equity Foundation (IBEF), InterMune, Islamic Food and Nutrition Council of America (IFANCA), Janssen Biotech, JC Biological Technologies, Knight Therapeutics, Kohlberg Kravis Roberts, Lonza Group, Lundbeck, Lupin, Medi-Caps, Medicaps, Ltd., Mitsubishi Chemical Holdings Corporation (Qualicaps, Inc.), MW Encap, Ltd., Nanjing Saturn Pharmaceutical Technology Company, Ltd., National Institutes of Health (NIH), Natural Capsules, NecLife, Nectar Lifesciences, Nicholas Piramal India, Ltd., Novartis, Organisation for Economic Co-operation and Development (OECD), Patheon, Pew Research Center's Forum of Religion and Public Life, Pfizer, Pharma (Nanjing) Company, Ltd., Pharmacyclics, Qingdao Yiqing Medicinal Capsules Company, Qualicaps, Ranbaxy Laboratories, Roche, Rousselot, Roxlor, Sanofi, SavoiurCaps, Shanxi Gaungsheng Medicinal Capsule Company, Ltd., Shaoxing Kangke Capsule Company, Snail Pharma Industry Company, Suheung, SUNIL HEALT Capscanada Corporation, Tessenderlo Group, Torrent Pharma, Vanda Pharmaceuticals, Warner–Lambert, World Health Organisation, Wuhan Carma Technology Company, and Zhejiang Erawat Pharma Limited.. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).